Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic Mycobacterium tuberculosis strains

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 11, 1998, Pages 3035-3037

  Deidda, Delia ^a   Lampis, Giorgio ^a   Fioravanti, Rossella ^b   Biava, Mariangela ^b   Porretta, Giulio Cesare ^b   Zanetti, Stefania ^c   Pompei, Raffaello ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF SASSARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 BIS(4 CHLOROPHENYL) 2 METHYL 3 (4 METHYL 1 PIPERAZINYLMETHYL)PYRROLE; PIPERAZINE DERIVATIVE; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; DERIVATIZATION; DRUG EFFECT; DRUG POTENCY; GROWTH INHIBITION; HISTIOCYTIC LYMPHOMA; MACROPHAGE ACTIVATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

EID: 0031753303     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.11.3035     Document Type: Article

References (22)

1. Arain, T. M., A. E. Resconi, D. C. Singh, and C. K. Stover. 1996. Reporter gene technology to assess activity of antimycobacterial agents in macrophages. Antimicrob. Agents Chemother. 40:1542-1544.
2. Ashtekar, D. R., R. Costa-Perira, K. Hagrajan, M. Vishvamatham, A. D. Bhatt, and W. Rittel. 1993. In vitro and in vivo activities of the nitroimidazole CGI17341 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 37:183-186.
3. Biava, M., R. Fioravanti, G. C. Porretta, G. Sleiter, A. Ettorre, D. Deidda, G. Lampis, and R. Pompei. 1997. New toluidine derivatives with antimycobacterial and antifungal activities. Med. Chem. Res. 7:228-250.
4. Brown, B. A., J. M. Swenson, and R. J. Wallace. 1992. Broth microdilution MIC test for rapidly growing mycobacteria, p. 5.11.1-5.11.10. In H. D. Isenberg (ed.), Clinical microbiology procedures handbook, vol. 1. American Society for Microbiology, Washington, D.C.
5. Cerreto, F., A. Villa, A. Retico, and M. Scalzo. 1992. Studies on anti-Candida agents with a pyrrole moiety: synthesis and microbiological activity of some 3-aminomethyl-1, 5-diaryl-2-methyl-pyrrole derivatives. Eur. J. Med. Chem. 27:701-708.
6. Collins, F. M. 1989. Mycobacterial disease, immunosuppression, and acquired immunodeficiency syndrome. Clin. Microbiol. Rev. 2:360-377.
7. Dooley, S. W., W. R. Jarvis, W. J. Marone, and D. E. Snider. 1992. Multidrug resistant tuberculosis. Ann. Intern. Med. 117:257-259.
8. Fioravanti, R., M. Biava, S. Donnarumma, G. C. Porretta, M. Simonetti, A. Villa, A. Porta-Puglia, D. Deidda, C. Maullu, and R. Pompei. 1996. Synthesis and microbiological evaluation of (N-heteroaryl)arylmethanamines and their Shiff bases. II Farmaco 51:643-652.
9. Fioravanti, R., M. Biava, G. C. Porretta, M. Artico, G. Lampis, D. Deidda, and R. Pompei. 1997. N-substituted 1-aryl-2(1H-imidazol-1-yl)1-ethanamines with broad spectrum in vitro antimycobacterial and antifungal activities. Med. Chem. Res. 7:87-97.
10. Fischl, M. A., G. L. Daikos, R. B. Uttamchandani, R. B. Poblete, J. M. Moreno, R. R. Reyes, A. M. Boota, L. M. Thompson, T. J. Cleary, G. A. Oldham, M. J. Saldama, and S. Lai. 1992. Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug-resistant bacilli. Ann. Intern. Med. 117:184-190.
11. Heifets, L. 1996. Susceptibility testing of Mycobacterium avium complex isolates. Antimicrob. Agents Chemother. 40:1759-1767.
12. Heym, B., N. Honorè, C. Truffot-Pernot, A. Banerjee, C. Schurra, W. R. Jacobs, J. D. A. van Embden, J. H. Grosset, and S. T. Cole. 1994. Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis: a molecular study. Lancet 344:293-298.
13. Inderlied, C. B., and M. Salfinger. 1996. Antimicrobial agents and susceptibility tests: mycobacteria, p. 1385-1404. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Volken (ed.), Manual of clinical microbiology, 5th ed. American Society for Microbiology, Washington, D.C.
14. Kochi, A. 1991. Global tuberculosis situation and the control strategy of WHO. Tubercle 72:1-6.
15. Lee, C., and L. Heifets. 1987. Determination of minimal inhibitory concentrations of anti-tuberculosis drugs by radiometric and conventional methods. Ann. Rev. Respir. Dis. 136:349-352.
16. Moor, N., and L. Heifets. 1993. MICs and MBCs of clarithromycin against Mycobacterium avium within human macrophages. Antimicrob. Agents Chemother. 37:111-114.
17. National Committee for Clinical Laboratory Standards. 1995. Antimycobacterial susceptibility testing. Proposed standard M24-P National Committee For Clinical Laboratory Standards, Villanova, Pa.
18. Pearson, M. L., J. A. Jereb, T. R. Frieden, J. T. Crawford, B. J. Davis, S. W. Dooley, and W. R. Jarvis. 1992. Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis. A risk to patients and health care workers. Ann. Intern. Med. 117:191-196.
19. Riley, L. W. 1993. Drug-resistant tuberculosis. Clin. Infect. Dis. 17:S442-S446.
20. Sbarbaro, J. A., M. D. Iseman, and A. J. Crowle. 1992. The combined effect of rifampin and pyrazinamide within the human macrophage. Am. Rev. Respir. Dis. 146:1448-1451.
21. 937). Int. J. Cancer 7:565-577.
22. Wayne, L. G., and H. A. Sramek. 1994. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 38:2054-2058.